NervGen is a late-stage clinical biopharmaceutical company developing neuroreparative therapies for spinal cord injuries. According to NervGen, there are currently no FDA-approved drug therapies that restore lost neurological functions in people with chronic spinal cord injuries. According to the company, the designation is intended to accelerate the development and review of treatments for serious conditions when preliminary clinical data indicate a potential substantial improvement over existing therapies on at least one clinically significant endpoint. According to NervGen, benefits include eligibility for priority review, rolling submission of the application for approval and organizational support from the FDA in determining an efficient pathway to approval. The company also emphasizes that the designation does not guarantee approval of NVG-291 and that earlier trial results do not necessarily predict later results.
The trial underlying the designation
According to NervGen, the designation is based on the FDA's review of safety and efficacy data from the chronic cohort of the Phase 1b/2a CONNECT SCI trial. According to the trial registry ClinicalTrials.gov, CONNECT SCI was a randomized, double-blind, placebo-controlled trial with a total of 24 enrolled participants that began on August 8, 2023, and was completed on January 21, 2026. According to a NervGen announcement dated November 24, 2025, the mean improvement in hand function at week 16, measured by the GRASSP prehension test, was 3.7 times greater with NVG-291 than with placebo. Of the participants treated with NVG-291, 75 percent (6 of 8) described their symptoms overall as much or very much improved, compared with 33 percent (3 of 9) receiving placebo. NVG-291 was generally well tolerated, with no serious adverse events or treatment discontinuations. According to NervGen, the drug is a subcutaneously administered peptide that targets the inhibitory CSPG-PTPσ signaling pathway and is intended to promote nerve tissue repair.
Andrew Wagner, executive director of Wings for Life USA, an organization that says it supports clinical research to improve prospects for recovery and that supported the CONNECT SCI trial, said they were encouraged by the progress with NVG-291.
The Phase 3 RESTORE trial is intended to enroll around 150 people
On October 12, 2026, NervGen had already announced that the first participant in the Phase 3 registrational trial RESTORE had received treatment. RESTORE is, according to NervGen, a multicenter, randomized, double-blind, placebo-controlled Phase 3 trial intended to enroll around 150 adults with chronic motor-incomplete cervical spinal cord injuries at up to 60 trial sites in the United States and Canada. According to the criteria, eligible participants are people whose traumatic injury occurred one to ten years earlier, whose motor level is C7 or higher on both sides and who are classified as C or D on the ASIA Impairment Scale. Participants are to receive NVG-291 or placebo in a 1:1 ratio, each as a once-daily subcutaneous injection for 12 weeks, followed by a four-week observation period. According to NervGen, the primary endpoint is improvement in hand function measured by GRASSP Quantitative Prehension; secondary endpoints and blinded participant interviews are also intended to assess independence and quality of life. According to a November 7, 2026, update in the Canadian trial registry, the trial is listed as recruiting overall; the sites in Edmonton and Vancouver were listed as “Not yet recruiting” at that time. Health Canada had previously confirmed on September 10, 2026, that the trial met regulatory requirements.
The value of the designation and what remains unresolved
For the accelerated approvals examined in the cross-sectional study “Premarket Pivotal Trial End Points and Postmarketing Requirements for FDA Breakthrough Therapies,” the FDA required additional studies to confirm efficacy after approval in every case, according to the authors; for traditional approvals based on surrogate markers, this was the case in 4 of 61 cases (7 percent). According to a report by Orthopedics This Week, about 312,000 people in the United States live with a traumatic spinal cord injury, with around 18,500 new cases each year. RESTORE's precise timeline also remains unresolved: the ClinicalTrials.gov registry estimates completion of primary data collection in July 2027, while NervGen, in an announcement dated October 12, 2026, had expected recruitment to end in the second half of 2027 and initial summary results in the first half of 2028. According to an announcement dated November 24, 2025, NervGen holds the exclusive worldwide rights to NVG-291; according to that announcement, all further clinical development plans were dependent on additional funding at the time.
Who is eligible for the RESTORE trial
According to the trial registry, adults aged 18 to 75 are eligible for RESTORE; time since injury is determined at randomization. According to the trial registry, the ASIA classification of C or D must be present at screening. After completion of the main trial, an optional, open-label extension study lasting a further twelve weeks is planned, in which participants originally assigned to the placebo group could also gain access to NVG-291. Whether enough participants can be found and whether the effects seen so far are confirmed in the larger, placebo-controlled Phase 3 trial will be shown by the completion of recruitment, expected in the second half of 2027 according to NervGen, and the initial summary results expected in the first half of 2028.
